

Figure 1

SUBSTITUTE SHEET (RULE 26)

WO 2005/004592

PCT/IB2004/002374

2/7




Figure 2.







a**b**


Figure 3

WO 2005/004592

PCT/IB2004/002374

4/7

Figure 4



WO 2005/004592

PCT/IB2004/002374

5/7

HLA-A2+ DR1+ CI- CII-AC anti-PreS2 response following a pcmv S2/S immunization




Figure 5

HLA-A2+DR1+CI-CII-T CD4 proliferative response to
HLA-DR1 restricted epitopes following immunization
with pcmv S2-S





Figure 6

SUBSTITUTE SHEET (RULE 26)

WO 2005/004592

PCT/IB2004/002374

7/7

HLA-A2+ DR1+ CI- CII-mice T CD8 cytotoxic response to the HLA-A2 restricted HBS (348-357) peptide following an immunization with pcmy S2/S




Figure 7